GLP-1 medications, semaglutide, tirzepatide, and the drugs that have followed them, are probably the biggest story in medicine right now. The weight loss is real. The metabolic improvements are real. For a lot of patients, these drugs have done more for their health in a year than a decade of dieting managed to do.
But there's a piece of this story that isn't getting nearly enough attention outside of clinical circles: a meaningful share of the weight coming off isn't fat. It's muscle.
What the data actually shows
Across several major trials, lean mass has accounted for roughly a quarter to as much as 40% of total weight lost on higher-dose GLP-1 therapy, a notably higher share than what's typically seen with calorie restriction alone. That's not a rounding error. Muscle isn't just about strength and appearance, it's metabolically active tissue. One expert at this year's American Diabetes Association Scientific Sessions put a number on it: each kilogram of muscle lost costs you roughly 13 kilocalories of daily resting energy expenditure, compared to about 4 kilocalories for a kilogram of fat. Lose enough muscle, and you're not just smaller, you're running a slower metabolic engine than before you started.
The stakes are highest for older adults. Sarcopenia, the age-related loss of muscle mass and strength, already affects roughly one in three adults over 60 and is a major driver of falls, fractures, and loss of independence. Layer significant additional muscle loss on top of that baseline, and the risk isn't cosmetic. It's functional. Some research has found measurable declines in grip strength and basic mobility tasks in older patients losing large amounts of weight quickly on these medications.
To be fair to the science, this picture is still evolving, and it isn't uniformly alarming. Some newer body composition research has found that muscle quality, not just quantity, may actually improve on these drugs, with less fat infiltration into muscle tissue even as total lean mass drops. The honest summary is that the risk is real, it isn't evenly distributed across every patient, and it's very manageable when it's actually addressed instead of ignored.
This isn't really a drug problem. It's a systems problem.
Here's how I think about it, the same way I think about any healthcare system: the body doesn't preserve tissue it isn't getting a signal to keep. Rapid, large-scale weight loss, whatever is driving it, removes calories faster than the body would lose them on its own. Without a strong countervailing signal, mainly resistance training and adequate protein, muscle gets treated as expendable right alongside fat.
That's not a flaw unique to GLP-1 drugs. It's what happens with any aggressive weight loss intervention that isn't paired with the inputs that tell the body which tissue to protect. The difference is that GLP-1s produce enough weight loss, fast enough, that the problem shows up at a scale worth taking seriously.
What actually preserves muscle
This is the part that should get more attention than it does, because the answer isn't complicated, and it's backed by real trial data, not speculation.
The S-LITE trial paired liraglutide with supervised resistance and aerobic training. Patients didn't just preserve muscle, they gained lean mass, an outcome pharmacotherapy alone didn't produce. A separate line of research has converged on a protein target of roughly 1.2 to 1.6 grams per kilogram of body weight per day as the range that supports muscle retention during active weight loss, with diminishing returns above that. Trials specifically designed around semaglutide and tirzepatide are now testing structured resistance training and protein targets together, precisely because the two appear to work better in combination than either does alone.
In practice, that means: resistance training several days a week, not just cardio. Protein at every meal, not an afterthought. And for patients starting these medications, especially older adults or anyone with a lower starting muscle mass, a conversation with your prescribing physician about tracking body composition, not just the number on the scale.
Where the science is headed
Some of the most interesting early research is looking at whether the muscle loss problem can be addressed pharmacologically rather than only behaviorally. A phase 2 trial combining semaglutide with bimagrumab, a drug that blocks a pathway called myostatin that normally limits muscle growth, brought the lean-mass share of total weight loss down to roughly 7%, a fraction of what's typically seen with semaglutide alone. That's early-stage research, not an available treatment, but it tells you where serious researchers think the next generation of these therapies needs to go.
The goal was never just to weigh less. The goal is to be a stronger, more capable version of yourself at a lower weight, not a smaller, weaker one.
The takeaway
GLP-1 medications are a genuine advance, not a fad, and I don't think the muscle mass conversation should scare anyone away from them. But treating the drug as the whole intervention, rather than one part of a system that also needs resistance training, adequate protein, and some actual monitoring, is how patients end up lighter and weaker instead of lighter and stronger. If you're on one of these medications or considering it, that's worth raising directly with whoever's prescribing it, not something to leave to the drug alone.